AOBO board announces $20 million share buyback program American Oriental Bioengineering.

AOBO board announces $20 million share buyback program American Oriental Bioengineering, Inc. , , a pharmaceutical company focused on improving health through the development, manufacture and commercialization of a wide range of prescription and over-the-counter items, announced at its 2010 earnings conference call, held on March 15, 2011, that its board of directors certified a share buyback system for the repurchase of up to $20 million of the business’s outstanding common share over another two years. Purchases under this scheduled plan may be made, from time to time, in the open market, negotiated transactions privately, block trades, and accelerated stock repurchase transactions or elsewhere, as determined by the ongoing company and will be funded from available functioning capital Can humans take doxycycline? .

Acknowledged as experts in cell culture Widely, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a variety of molecular recognition reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products consist of: Oncology, Regenerative Medication, Environmental Evaluation, Cytotoxicity Screening, Stem and Glycomics Cell Biology.. AMSBIO announces magnetic bead based device offering efficient alternative for DNA clean-up and size selection in NGS AMSBIO announces MagSi-NGSPREP – a magnetic bead based tool that provides an efficient answer for DNA clean-up and size selection in Next Generation Sequencing applications.